Interestingly, updated FDA recommendations for rhIGF-I usage in IGF-I deficiency conditions warn about increased occurrence of neoplasia, especially when used at higher dosages, including some rare malignancies not typically observed in children. The gene discussed is IGF1; the disease is hyperinsulinemic hypoglycemia, familial, 4.